Pharmaceutical executive Scott Plesha named CEO
Lead product ZELSUVMI expected to be commercially available in late 2024
Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
This press release features multimedia. View the full release here:
Scott Plesha, CEO, Pelthos Therapeutics (Photo: Business Wire)
Pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of...